Large study tracks rare side effect of schizophrenia shot
NCT ID NCT01088386
First seen Feb 01, 2026 · Last updated Apr 25, 2026 · Updated 10 times
Summary
This program monitors 4,000 people with schizophrenia who receive the injectable medication Zyprexa Relprevv. The goal is to track and reduce the risk of a rare but serious side effect called post-injection delirium/sedation syndrome (PDSS). Researchers will record how often PDSS happens and look for possible risk factors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
United BioSource Corporation
Blue Bell, Pennsylvania, 19422, United States
Conditions
Explore the condition pages connected to this study.